Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

National Institutes of Health–Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities

Open access
Ricordi, Camillo, Goldstein, Julia S., Balamurugan, A.N., Szot, Gregory L., Kin, Tatsuya, Liu, Chengyang, Czarniecki, Christine W., Barbaro, Barbara, Bridges, Nancy D., Cano, Jose, Clarke, William R., Eggerman, Thomas L., Hunsicker, Lawrence G., Kaufman, Dixon B., Khan, Aisha, Lafontant, David-Erick, Linetsky, Elina, Luo, Xunrong, Markmann, James F., Naji, Ali, Korsgren, Olle, Oberholzer, Jose, Turgeon, Nicole A., Brandhorst, Daniel, Chen, Xiaojuan, Friberg, Andrew S., Lei, Ji, Wang, Ling-jia, Wilhelm, Joshua J., Willits, Jamie, Zhang, Xiaomin, Hering, Bernhard J., Posselt, Andrew M., Stock, Peter G., Shapiro, A.M. James · 2016 · Diabetes

Abstract

Eight manufacturing facilities participating in the National Institutes of Health–sponsored Clinical Islet Transplantation (CIT) Consortium jointly developed and implemented a harmonized process for the manufacture of allogeneic purified human pancreatic islet (PHPI) product evaluated in a phase 3 trial in subjects with type 1 diabetes. Manufacturing was controlled by a common master production batch record, standard operating procedures that included acceptance criteria for deceased donor organ pancreata and critical raw materials, PHPI product specifications, certificate of analysis, and test methods. The process was compliant with Current Good Manufacturing Practices and Current Good Tissue Practices. This report describes the manufacturing process for 75 PHPI clinical lots and summarizes the results, including lot release. The results demonstrate the feasibility of implementing a harmonized process at multiple facilities for the manufacture of a complex cellular product. The quality systems and regulatory and operational strategies developed by the CIT Consortium yielded product lots that met the prespecified characteristics of safety, purity, potency, and identity and were successfully transplanted into 48 subjects. No adverse events attributable to the product and no cases of primary nonfunction were observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db16-0234

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 196

Metadata

Authors
Ricordi, C., Goldstein, J. S., Balamurugan, A. N., Szot, G. L., Kin, T., Liu, C., Czarniecki, C. W., Barbaro, B., Bridges, N. D., Cano, J., Clarke, W. R., Eggerman, T. L., Hunsicker, L. G., Kaufman, D. B., Khan, A., Lafontant, D.-E., Linetsky, E., Luo, X., Markmann, J. F., Naji, A., Korsgren, O., Oberholzer, J., Turgeon, N. A., Brandhorst, D., Chen, X., Friberg, A. S., Lei, J., Wang, L.-J., Wilhelm, J. J., Willits, J., Zhang, X., Hering, B. J., Posselt, A. M., Stock, P. G., & Shapiro, A. M. J.
Venue
Diabetes
Published
2016-07-27
Volume
65
Issue
11
Pages
3418-3428
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2539044895
Cited by
196
References
4
FWCI
22.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: National Institutes of Health–Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. https://app.cochat.ai/papers/10.2337/db16-0234
The paper
Ricordi, C., Goldstein, J. S., Balamurugan, A. N., Szot, G. L., Kin, T., Liu, C., Czarniecki, C. W., Barbaro, B., Bridges, N. D., Cano, J., Clarke, W. R., Eggerman, T. L., Hunsicker, L. G., Kaufman, D. B., Khan, A., Lafontant, D.-E., Linetsky, E., Luo, X., Markmann, J. F., . . . Shapiro, A. M. J. (2016). National Institutes of Health–Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes. https://doi.org/10.2337/db16-0234

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.